Alpha-crystalline domain proteins and their use in genome modification

EP4762184A2Pending Publication Date: 2026-06-24RGT UNIV OF CALIFORNIA
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
RGT UNIV OF CALIFORNIA
Filing Date
2024-08-16
Publication Date
2026-06-24

AI Technical Summary

Technical Problem

Current genome modification methods, such as genome editing, suffer from low efficiency and high occurrence of off-target modifications, leading to unintended consequences and uncontrolled changes to non-targeted cellular pathways.

Method used

The method involves providing a eukaryotic cell with a genetic modifier polypeptide and an α-crystalline domain polypeptide, both capable of being targeted to a specific nucleic acid. These polypeptides are recombinant and may include heterologous targeting domains, such as DNA-binding domains or the Sticky-C domain, to facilitate precise targeting using systems like SunTag-based targeting.

Benefits of technology

This approach enhances the efficiency of genome modification while reducing off-target effects, allowing for precise control of gene activity and cellular function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024042723_20022025_PF_FP_ABST
    Figure US2024042723_20022025_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates generally to methods of eukaryotic genome modification. More specifically, the present disclosure relates to compositions and. methods for targeting a. genetic modifier polypeptide and a a-crystalline domain polypeptide to a target nucleic acid of interest to facilitate a genome modification.
Need to check novelty before this filing date? Find Prior Art